BUZZ-Hims & Hers on track for third straight session of gains

Reuters11-25

BUZZ-Hims & Hers on track for third straight session of gains

** Shares of telehealth firm Hims & Hers HIMS.N rise 14% to $28.83 - on track for their third straight session of gains

** HIMS closed 5% higher on Friday, and rose nearly 11% in Thursday's session

** Stock has more than tripled this year, helped in part by its offering of compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy

** HIMS also offers treatments for a range of conditions, including sexual health, men's and women's skin health, and mental health

** Late on Friday, U.S. president-elect Donald Trump nominated surgeon and writer Martin Makary to lead the Food and Drug Administration

** Makary is also the chief medical officer of another telehealth company called Sesame, that also offers compounded versions of Novo's Wegovy

** 12 of 13 brokerages rate HIMS' stock at "hold" or higher, 1 rates it "sell"; their median PT is $24

(Reporting by Bhanvi Satija in Bengaluru)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486003927?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486003927","market":"us","top_or_hot":-1,"title":"BUZZ-Hims & Hers on track for third straight session of gains","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers on track for third straight session of gains </title></head><body><p>** Shares of telehealth firm Hims &amp; Hers <span>HIMS.N</span> rise 14% to $28.83 - on track for their third straight session of gains </p><p>** HIMS closed 5% higher on Friday, and rose nearly 11% in Thursday's session </p><p>** Stock has more than tripled this year, helped in part by its offering of compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's <span>NOVOb.CO</span> Wegovy </p><p>** HIMS also offers treatments for a range of conditions, including sexual health, men's and women's skin health, and mental health </p><p>** Late on Friday, U.S. president-elect Donald Trump nominated surgeon and writer Martin Makary to lead the Food and Drug Administration</p><p>** Makary is also the chief medical officer of another telehealth company called Sesame, that also offers compounded versions of Novo's Wegovy </p><p>** 12 of 13 brokerages rate HIMS' stock at \"hold\" or higher, 1 rates it \"sell\"; their median PT is $24</p><p> (Reporting by Bhanvi Satija in Bengaluru)</p><p> ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hims & Hers on track for third straight session of gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hims & Hers on track for third straight session of gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 23:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3N3MW0QQ:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Hims & Hers on track for third straight session of gains ** Shares of telehealth firm Hims & Hers HIMS.N rise 14% to $28.83 - on track for their third straight session of gains ** HIMS closed 5% ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3N3MW0QQ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nL3N3MW0QQ:1","article_id":"2486003927","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486003927","pubTimestamp":1732550195,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hims & Hers on track for third straight session of gains ** Shares of telehealth firm Hims & Hers HIMS.N rise 14% to $28.83 - on track for their third straight session of gains ** HIMS closed 5% higher on Friday, and rose nearly 11% in Thursday's session ** Stock has more than tripled this year, helped in part by its offering of compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy ** HIMS also offers treatments for a range of conditions, including sexual health, men's and women's skin health, and mental health ** Late on Friday, U.S. president-elect Donald Trump nominated surgeon and writer Martin Makary to lead the Food and Drug Administration** Makary is also the chief medical officer of another telehealth company called Sesame, that also offers compounded versions of Novo's Wegovy ** 12 of 13 brokerages rate HIMS' stock at \"hold\" or higher, 1 rates it \"sell\"; their median PT is $24  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务"},"translate_title":"BUZZ-Hims&Hers有望连续第三个交易日上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"BUZZ-Hims & Hers on track for third straight session of gains ** Shares of telehealth firm Hims & Hers HIMS.N rise 14% to $28.83 - on track for their third straight session of gains ** HIMS closed 5% higher on Friday, and rose nearly 11% in Thursday's session ** Stock has more than tripled this year, helped in part by its offering of compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy ** HIMS also offers treatments for a range of conditions, including sexual health, men's and women's skin health, and mental health ** Late on Friday, U.S. president-elect Donald Trump nominated surgeon and writer Martin Makary to lead the Food and Drug Administration** Makary is also the chief medical officer of another telehealth company called Sesame, that also offers compounded versions of Novo's Wegovy ** 12 of 13 brokerages rate HIMS' stock at \"hold\" or higher, 1 rates it \"sell\"; their median PT is $24 (Reporting by Bhanvi Satija in Bengaluru) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486003927"}